Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.

Content Provider	Europe PMC
Author	Chhabra, Sandeep Singh, Sukhraj P. Singh, Arshdeep Mehta, Varun Kaur, Amninder Bansal, Namita Sood, Ajit
Copyright Year	2021
Abstract	Background Diabetes mellitus is associated with an increased risk of development of non-alcoholic fatty liver disease (NAFLD). However, the risk posed by diabetes mellitus in progression of liver disease is uncertain. This study compared the severity of hepatic fibrosis in patients with NAFLD with and without diabetes mellitus. Methods Consecutive adult patients with NAFLD undergoing transient elastography [FibroScan Touch 502 (Echosens, Paris, France)] at a tertiary care center in north India were analyzed for severity of hepatic fibrosis. The aspartate aminotransferase (AST) to platelet ratio index (APRI), fibrosis index based on 4 factors (FIB-4), and NAFLD Fibrosis Score (NFS) were calculated. The degree of hepatic fibrosis as determined by FibroScan and non-invasive serum fibrosis models in patients with and without diabetes mellitus were compared. Results A total of two hundred patients [118 (59%) males, mean age 50.30 ± 11.13 years] were enrolled. Significant hepatic fibrosis was present in 86 (43%) patients [mean age 50.66 ± 10.96 years, 56 (65.11%) males]. The mean FibroScan, APRI, FIB-4, and NFS scores were 9.86 ± 2.97, 0.75 ± 0.47, 2.41 ± 1.41 and −0.24 ± 1.43 in patients with diabetes compared to 5.31 ± 1.09, 0.49 ± 0.27, 1.55 ± 0.85, and −2.12 ± 1.88 in patients without diabetes, respectively (P=<0.0001). There was a fair correlation between FibroScan and non-invasive serum fibrosis models (P=<0.0001). Conclusion Presence of diabetes increases the risk of significant hepatic fibrosis in patients with NAFLD. FIB-4 correlates fairly with FibroScan in patients with diabetes and can be used as a screening tool to detect significant hepatic fibrosis.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9077176&blobtype=pdf
ISSN	09736883
Volume Number	12
DOI	10.1016/j.jceh.2021.07.001
PubMed Central reference number	PMC9077176
Issue Number	2
PubMed reference number	35535092
Journal	Journal of Clinical and Experimental Hepatology [J Clin Exp Hepatol]
e-ISSN	22133453
Language	English
Publisher	Elsevier
Publisher Date	2021-07-09
Access Restriction	Open
Rights License	© 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V.
Subject Keyword	diabetes mellitus non-alcoholic fatty liver disease fibrosis liver cirrhosis ALT, Alanine aminotransferase APRI, Aspartate aminotransferase to platelet ratio index AST, Aspartate aminotransferase DM, Diabetes Mellitus FIB-4, Fibrosis index based on 4 factors HbA1C, Glycosylated hemoglobin HDL, High-density lipoprotein IFG, Impaired fasting glucose LDL, Low-density lipoprotein NAFLD, Non-alcoholic fatty liver disease NASH, Non-alcoholic steatohepatitis NFS, NAFLD Fibrosis Score TE, Transient Elastography
Content Type	Text
Resource Type	Article
Subject	Hepatology